Keyphrases
Mouse Model
100%
Age-dependent
100%
Therapeutic Effect
100%
Memantine
100%
Juvenile Batten Disease
100%
Motor Coordination
66%
Cortex
33%
N-methyl-D-aspartate Receptor (NMDAR)
33%
CLN3
33%
Acute Inhibition
33%
Postnatal Day
16%
Disease Progression
16%
Microglial Activation
16%
Glutamate Receptors
16%
Methyl
16%
Neurodegenerative Diseases
16%
N-methyl-D-aspartate
16%
Non-competitive
16%
Attenuation
16%
Amino
16%
Astrocytosis
16%
Beneficial Effects
16%
Acute Treatment
16%
Repeated Administration
16%
New Drug Targets
16%
Disease Stage
16%
Pathomechanism
16%
Neuron Population
16%
Day 14
16%
AMPA-type Glutamate Receptor
16%
Motor Skills
16%
Human Disorders
16%
Astrocytic Activation
16%
Repeated Treatment
16%
AMPA Antagonist
16%
Glutamate Receptor Activity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Therapeutic Effect
100%
Neuronal Ceroid Lipofuscinosis
100%
Memantine
100%
Dextro Aspartic Acid
50%
Diseases
50%
Receptor
33%
Alpha Amino 3 Hydroxy 5 Methyl 4 Isoxazolepropionic Acid
33%
Glutamate Receptor
33%
Disease Exacerbation
16%
Astrocytosis
16%
Neuroscience
Neuronal Ceroid Lipofuscinosis
100%
Memantine
100%
Motor Coordination
66%
Dextro Aspartic Acid
50%
Glutamate Receptor
33%
AMPA
33%
Receptor
33%
Neurodegenerative Disorder
16%
Motor Skills
16%